Clinical trial
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
NCT00127283 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00127283 |
|---|---|
| Title | Recombinant Factor VIIa in Acute Intracerebral Haemorrhage |
| Official title | Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage |
| Acronym | FAST |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Intracerebral Haemorrhage |
| Intervention type | Drug |
| Interventions | eptacog alfa (activated) |
| Enrollment | 829 |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Aug 5, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Denmark, Finland, France, Germany, Hong Kong and 11 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: